AstraZeneca PLCAZN
▲ PositiveTechnologyrelevance
COPD drug tozorakimab met primary endpoints in two Phase 3 trials, reducing flare-ups, with FDA priority review.
Impact on stocks 1
Biotech & Genomic Medicine
AstraZeneca PLCAstraZeneca's shares fell about 1.3% to $158 on Wednesday, even after its experimental COPD treatment, tozorakimab, met primary endpoints in two Phase 3 trials. The drug reduced moderate or severe flare-ups by 29% and 34% among former smokers in the OBERON and TITANIA studies, respectively, with reductions of roughly 30% and 29% across broader patient groups. The trials involved 2,306 patients, and no new safety signals were identified. The FDA has granted priority review, with a decision expected in the first quarter of 2027. AstraZeneca reported first-half revenue of $30.7 billion and core operating profit of $10.5 billion, implying a 34.2% margin. At $158, the stock trades 12.48% below its GF Value estimate of $180.52, suggesting potential upside if the drug gains approval and commercial success.
AstraZeneca PLCCOPD drug tozorakimab met primary endpoints in two Phase 3 trials, reducing flare-ups, with FDA priority review.